Please login to the form below
Vividion Therapeutics
This page shows the latest Vividion Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Tavros Therapeutics and Vividion Therapeutics collaborate in oncology programmes
Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal. ... Tavros Therapeutics has teamed up with biopharma Vividion Therapeutics – a wholly owned and independently operated subsidiary of Bayer AG – in a
Latest news
-
Celgene bulks up pipeline again with $2.1bn Prothena deal
smaller $101m collaboration with Vividion Therapeutics that also covers cancer and inflammatory diseases targets.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
- Medscape Oncology’s Large Presence at ASH 2023
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
